Disease · MONDO_0017137

onchocerciasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. onchocerciasis. Diseases, record MONDO_0017137. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017137

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: onchocerciasis; Open Targets
Open Targets ID: MONDO_0017137; Open Targets
Other names: Infection by Onchocerca volvulus (disorder), Onchocerca volvulus infection, infection by Onchocerca volvulus, volvulosis; Open Targets
Disease Ontology: DOID:11678; Disease Ontology
MeSH: D009855; MeSH
NCI Thesaurus: C34861; NCI Thesaurus
Orphanet: ORPHA:2737; Orphanet
Highest stage of its drugs: Approval, for 2 of its 8 drugs, from DailyMed, FDA and TTD; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
IVERMECTIN	CHEMBL6067487		Approval	DailyMed and TTD	15	13	13	Drugs and targets
MOXIDECTIN	CHEMBL2104415	Small molecule	Approval	DailyMed, FDA and TTD	11	8	8	Drugs and targets
ALBENDAZOLE	CHEMBL1483	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
DIETHYLCARBAMAZINE	CHEMBL684	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
EMODEPSIDE	CHEMBL2104404	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUBENTYLOSIN	CHEMBL4649378	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RIFAMPIN	CHEMBL374478	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04311671	Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole	Phase 3	12,979	2026-02-05	Onchocerciasis	IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT04188301	Safety and Efficacy of IDA for Onchocerciasis	Phase 2	154	2023-05-10	Onchocerciasis	ALBENDAZOLE, DIETHYLCARBAMAZINE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT04913610	Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection	Phase 2	153	2024-09-19	Onchocerciasis	ALBENDAZOLE, FLUBENTYLOSIN	Its record names the disease	ClinicalTrials.gov
NCT03962062	A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years	Phase 1	36	2025-01-22	Onchocerciasis	MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT07145736	Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical Diseases	Phase 4	52,000		Onchocerciasis, Ascaris Lumbricoides Infection, Trichuris Trichiura; Infection, Hookworm Infections, Scabies	IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT01905436	Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia		21,862		Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT02032043	Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)		14,457		Lymphatic Filariasis, Onchocerciasis, Soil Transmitted Helminth (STH) Infections	ALBENDAZOLE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov
NCT00790998	Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection	Phase 3	1,497		Onchocerciasis	IVERMECTIN, MOXIDECTIN	Its record names the disease	ClinicalTrials.gov
NCT05180461	Emodepside Phase II Trial for Treatment of Onchocerciasis	Phase 2	578		Onchocerciasis	EMODEPSIDE	Its record names the disease	ClinicalTrials.gov
NCT00001230	Host Response to Infection and Treatment in Filarial Diseases		425		Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis	DIETHYLCARBAMAZINE, IVERMECTIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40707999	RESULT	1	PubMed
29361335	RESULT	1	PubMed
24968000	RESULT	1	PubMed
38587077	DERIVED	1	PubMed
37243712	DERIVED	1	PubMed
37205721	DERIVED	1	PubMed
35476631	DERIVED	1	PubMed
33674871	DERIVED	1	PubMed
32976514	DERIVED	1	PubMed
32561912	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017137

GET https://conductscience.org/api/diseases/v1/MONDO_0017137/drugs

API reference For AI assistants